Nicoletta Loggia
Chief Tech/Sci/R&D Officer presso ORCHARD THERAPEUTICS PLC
Patrimonio netto: - $ in data 31/03/2024
Profilo
Nicoletta Loggia is an Independent Director at Candel Therapeutics, Inc. and the Chief Technical Officer at Orchard Therapeutics Plc.
She holds a doctorate degree from the University of Pavia.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Nicoletta Loggia
| Società | Posizione | Inizio |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 09/09/2021 |
| CANDEL THERAPEUTICS, INC. | Director/Board Member | 07/06/2023 |
Formazione di Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Nicoletta Loggia
